|1.||Robak, Tadeusz: 12 articles (12/2015 - 02/2008)|
|2.||Jewell, Roxanne C: 10 articles (10/2015 - 04/2012)|
|3.||Lisby, Steen: 9 articles (10/2015 - 11/2011)|
|4.||Czuczman, Myron S: 8 articles (10/2015 - 06/2010)|
|5.||Stilgenbauer, Stephan: 5 articles (12/2015 - 04/2010)|
|6.||Montillo, Marco: 5 articles (12/2015 - 07/2014)|
|7.||Kipps, Thomas J: 5 articles (10/2015 - 04/2010)|
|8.||Gupta, Ira V: 5 articles (08/2015 - 11/2011)|
|9.||Hillmen, Peter: 5 articles (08/2015 - 04/2010)|
|10.||Wierda, William G: 5 articles (08/2015 - 04/2010)|
|1.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
02/01/2016 - "In a recently published phase 3 trial (RESONATE) that compared ibrutinib and ofatumumab for the treatment of relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, ibrutinib at the daily dosage of 420 mg demonstrated a significantly higher overall response rate (43% in ibrutinib vs. 4% in ofatumumab) and a significantly improved overall survival at 12 months (90% ibrutinib vs. 81% ofatumumab). "
02/01/2008 - "Safety and efficacy of the fully human anti-CD20 monoclonal antibody, ofatumumab, was analyzed in a multicenter dose-escalating study including 33 patients with relapsed or refractory chronic lymphocytic leukemia. "
02/01/2008 - "Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study."
10/01/2015 - "An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia."
08/13/2015 - "Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study."
10/01/2014 - "In this study, for the first time, we examined pro-apoptotic activity of SMIP-016 in combination with monoclonal anti-CD20 antibody, ofatumumab (HuMax-CD20) in de novo chronic lymphocytic leukaemia (CLL) cells and in different B-cell neoplasm-derived lines. "
11/01/2015 - "Haematological cancer: PROLONGing PFS with ofatumumab in patients with CLL."
10/01/2015 - "Ofatumumab also delayed tumor progression and prolonged survival in a murine model of MCL. "
10/01/2013 - "In vivo, GA101 induced a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab. "
03/15/2013 - "These data demonstrate that GA101 and ofatumumab are both superior to rituximab against CLL cells via different mechanisms of potential tumor elimination. "
|3.||Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
06/15/2008 - "First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial."
05/01/2012 - "Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma."
07/25/2013 - "We performed a multi-center phase II trial investigating the safety and efficacy of ofatumumab, a monoclonal antibody against CD20, combined with ICE or DHAP second-line therapy in patients with relapsed or refractory DLBCL, grade 3b follicular lymphoma, or transformed follicular lymphoma. "
04/19/2012 - "Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study."
07/01/2014 - "The population pharmacokinetics of intravenous ofatumumab were characterized in patients with relapsed/refractory chronic lymphocytic leukemia, relapsed/refractory follicular lymphoma, and rheumatoid arthritis, diseases with widely varying CD20⁺ B-cell counts in blood. "
|4.||Non-Hodgkin Lymphoma (Lymphosarcoma)
06/15/2008 - "In a phase 1/2 trial evaluating safety and efficacy of ofatumumab in relapsed or refractory follicular non-Hodgkin lymphoma (FL) grade 1 or 2, 4 dose groups of 10 patients received 4 weekly infusions of 300, 500, 700, or 1000 mg. Patients had a median of 2 prior FL therapies and 13% had elevated lactate dehydrogenase. "
04/01/2015 - "Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma."
04/01/2015 - "The efficacy/tolerability of bendamustine, a unique alkylator, plus ofatumumab, a human anti-CD20 monoclonal antibody, was evaluated for previously untreated indolent B cell non-Hodgkin's lymphoma (NHL). "
10/01/2011 - "Ofatumumab activity has also been shown in a variety of other malignant and nonmalignant conditions, including non-Hodgkin lymphoma, rheumatoid arthritis, and multiple sclerosis. "
08/01/2012 - "Ofatumumab has also shown potential in treating B cell non-Hodgkin's lymphoma, such as follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), and Waldenström's macroglobulinemia. "
08/01/2010 - "To investigate the safety and efficacy of ofatumumab, a novel human anti-CD20 monoclonal antibody (mAb), in patients with active rheumatoid arthritis (RA) whose disease did not respond to > or = 1 disease-modifying antirheumatic drug. "
07/01/2013 - "Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics."
08/01/2010 - "Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study."
07/01/2013 - "To investigate the safety and tolerability of a single subcutaneous (SC) dose of ofatumumab, a fully human anti-CD20 monoclonal antibody, in patients with rheumatoid arthritis (RA) taking background methotrexate (MTX). "
12/01/2011 - "To evaluate the efficacy and safety of intravenous ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, active rheumatoid arthritis (RA) patients despite methotrexate treatment. "
|4.||L-Lactate Dehydrogenase (Lactate Dehydrogenase)
|7.||Complement System Proteins (Complement)
|9.||Complement Factor H (Factor H)
|10.||Epidermal Growth Factor Receptor (EGF Receptor)
|3.||Drug Therapy (Chemotherapy)
|5.||Stem Cell Transplantation